menu
    • menu
    [{"orgOrder":0,"company":"Tianjin Medical University Cancer Institute and Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Tianjin Medical University Cancer Institute and Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tianjin Medical University Cancer Institute and Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Tianjin Medical University Cancer Institute and Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Xiangbei Welman Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Xiangbei Welman Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiangbei Welman Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xiangbei Welman Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Piperacillin Sodium

    Menu

    Piperacillin Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            B. Braun Medical

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            B. Braun Medical

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            B. Braun Gains FDA Approval for DUPLEX Delivery of Piperacillin Combo

                            Details : Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.

                            Product Name : Piperacillin and Tazobactam for Injection

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 09, 2025

                            Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Baxter Launches Zosyn Premix in US

                            Details : Zosyn is a combination of piperacillin sodium, which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria and tazobactam sodium having activity against bacteria due to its reduced affinity to penicil...

                            Product Name : Zosyn

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 04, 2023

                            Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rambam Health Care Campus

                            Israel arrow
                            SupplySide West
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections

                            Details : Piperacillin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Enterobacteriaceae Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 02, 2022

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rambam Health Care Campus

                            Israel arrow
                            SupplySide West
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resis...

                            Details : Piperacillin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Enterobacteriaceae Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 14, 2018

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NYU Langone Health

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            NYU Langone Health

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

                            Details : Piperacillin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Appendicitis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 14, 2016

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Yuhan Corporation

                            South Korea arrow
                            SupplySide West
                            Not Confirmed

                            Yuhan Corporation

                            South Korea arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea

                            Details : Piperacillin is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Otitis Media.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 29, 2016

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tianjin Medical University Cancer Institute and Hospital

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Tianjin Medical University Cancer Institute and Hospital

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia

                            Details : Piperacillin is a Antibiotic drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 22, 2013

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Xiangbei Welman Pharmaceuticals

                            China arrow
                            SupplySide West
                            Not Confirmed

                            Xiangbei Welman Pharmaceuticals

                            China arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System In...

                            Details : Piperacillin Sodium is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 03, 2013

                            Lead Product(s) : Piperacillin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth